J9037 – Injection, belantamab mafodotin-blmf, 0.5 mg
HCPCS Level II code · J codes: Drugs Administered Other Than Oral Method
HCPCS codeJ9037
- Long description
- Injection, belantamab mafodotin-blmf, 0.5 mg
- Short description
- Inj belantamab mafodot blmf
- Pricing indicator
51Drugs- Medicare coverage
CCarrier judgment – coverage decided by the Medicare contractor- BETOS category
O1DChemotherapy- Added
- April 1, 2021
- Last change
- April 1, 2025 – No change
- Termination date
- March 31, 2025
Frequently asked questions
What is HCPCS code J9037?
J9037 is a HCPCS Level II code for injection, belantamab mafodotin-blmf, 0.5 mg. It was discontinued on March 31, 2025.
Does Medicare cover J9037?
The HCPCS file lists coverage code C: Carrier judgment – coverage decided by the Medicare contractor. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby J codes
- J9029 – Intravesical instillation, nadofaragene firadenovec-vncg, per therapeutic dose
- J9030 – Bcg live intravesical instillation, 1 mg
- J9031 – Bcg (intravesical) per instillation
- J9032 – Injection, belinostat, 10 mg
- J9033 – Injection, bendamustine hydrochloride, not otherwise specified, 1 mg
- J9034 – Injection, bendamustine hcl (bendeka), 1 mg
- J9035 – Injection, bevacizumab, 10 mg
- J9036 – Injection, bendamustine hydrochloride, (belrapzo/bendamustine), 1 mg
- J9038 – Injection, axatilimab-csfr, 0.1 mg
- J9039 – Injection, blinatumomab, 1 microgram
- J9040 – Injection, bleomycin sulfate, 15 units
- J9041 – Injection, bortezomib, 0.1 mg
- J9042 – Injection, brentuximab vedotin, 1 mg
- J9043 – Injection, cabazitaxel, 1 mg
- J9044 – Injection, bortezomib, not otherwise specified, 0.1 mg
- J9045 – Injection, carboplatin, 50 mg
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.